PharmStars, the pharma-focused accelerator for digital health startups, is delighted to announce the graduation of 11 startups from its Fall 2022 program focused on “Innovations in Real-World Evidence (RWE).” The graduating startups successfully completed PharmaU, PharmStars’ 10-week education, and mentoring program. PharmaU culminated with a Showcase Event–held in Boston in early November–that brought together the participating startups and PharmStars’ seven innovation-minded pharma members.
PharmStars focuses on bridging the “pharma-startup gap” to help pharma and startups overcome partnership barriers. PharmStars’ unique PharmaU program provides education and mentorship to help startups more effectively partner with pharma.
The 11 members of the Fall 2022 cohort were selected in August 2022 following a highly competitive application process that attracted 75 applicants from 13 different countries. The selected startups each offer a unique digital health solution related to Real World Evidence. Their diverse array of digital health solutions includes novel remote patient monitoring techniques, new biomarkers, drug discovery tools, analytics tools, data annotation platforms, therapeutic-area data models, and novel RWE datasets.
At the Showcase Event, startups presented their solutions to PharmStars’ pharma members. The startups then had the chance to participate in one-on-one meetings with the members. More than 60 meetings took place over two days. Participating startups said the Showcase Event was extremely valuable and useful to their business.
Zainab Doctor, Vice President for Product at nference said, “I can’t imagine a way we could have gotten this far this quickly with so many pharma in parallel without deploying a much larger sales force.”
Startup CEO, Sameer Sontakey of Biostrap said, “Every single customer conversation at the Showcase was excellent. These have been the best one-on-ones that I’ve had with any pharma clients.”
The CEO of another, international startup agreed that the Showcase Event led to actionable next steps. “We walked away from the Showcase with immediate action items and continued conversations with everyone we met,” said Katheron Intson, CEO of Varient.
The following 11 digital health startups completed the Fall 2022 PharmStars accelerator: · Biostrap (Austin, TX): High-Resolution, Biosensor-based Digital Biomarker Platform · Celero Systems (Lincoln, MA): Continuous, Ingestible, One-Week, Physiological Monitoring Platform · Centaur Labs (Boston, MA): Scalable Data Annotation Platform for the Life Sciences · Citadel Discovery (Cambridge, MA): AI Platform Using DNA-Encoded Libraries (DELs) for Drug Discovery · Huma.AI (Palo Alto, CA): Powerful, User-Friendly Natural Language Processing Platform Optimized for the Generation of RWE · nference (Cambridge, MA): RWE Generation Platform Built on 11+ million Academic Medical Center Medical Records · Promptly Health (Porto, Portugal): Advanced Analytics Engine that Harmonizes Real-World Data to Generate Insights · Scienta Lab (Paris, France): AI-Powered Platform for Auto-immune Diseases Modeling at the Patient Level · uMed (London, England): Queryable, Dynamic Real-World Patient Cohorts for Prospective Population Research · Unison (London, England): Genomics Data Brokerage Platform · Varient (Toronto, Canada): Rare Disease Patient Community-Sourced Patient Reported Outcomes and RWE platform
For its Spring 2023 cohort, themed “Innovations in Women’s Health and Health Equity,” PharmStars is accepting applications until January 14, 2023. Digital health startups interested in participating can find information on dates and deadlines and the application form on the PharmStars website.
For pharma and biotech companies, PharmStars 2023 membership is now open to a limited number of additional firms.
About PharmStars PharmStars is the member-based, pharma-focused accelerator for digital health startups. Through our extensive expertise across pharma, startups, digital health, and innovation, we understand the challenges that pharma and startups face when seeking to collaborate. Our PharmaU program supports digital health startups and our pharma members in “bridging the pharma-startup gap,” leading to greater success and faster adoption of “beyond the molecule” solutions for patients.
PharmStars, the pharma-focused accelerator for digital health startups, is delighted to announce the graduation of 11 startups from its Spring 2022 program. The graduates successfully completed the 10-week PharmaU program, which culminated with the Showcase Event held June 8-10 in Boston. The Showcase Event brought together the participating startups and PharmStars’ seven innovation-minded pharma members.
PharmStars focuses on bridging the “pharma-startup gap” by helping pharma and startups overcome partnership barriers. PharmStars’ unique PharmaU program provides education and mentorship to help startups and pharma partner more effectively.
The newest cohort was selected in March 2022 following a competitive application process. Each startup offers a novel digital health solution related to the theme of “Innovations in Neurological Disease.” Their products represent a diverse array of digital health solutions, including digital biomarkers, digital therapeutics, remote patient monitoring, and patient engagement tools.
At the Showcase Event, startups presented their solutions and participated in one-on-one meetings with representatives of PharmStars’ pharma members. Participating startups said that the Showcase Event was extremely impactful.
“Normally, it takes years from an initial meeting to a serious conversation with a pharma company. In one day, we have the attention of six pharma companies specifically interested in what we can do! The opportunity is enormous,” said the CEO of one of the startups.
The CEO of another participating startup said, “We are an early-stage startup. For us, to have an opportunity to showcase our company to major pharma companies…is an occasion that we had not even considered possible. It’s not only the pharma companies’ audience but, most importantly, the ‘right’ people within pharma attended the event.”
The following 11 digital health startups successfully completed the PharmStars accelerator:
· Accexible (Barcelona, Spain): Rapid, remote, device-agnostic speech biomarkers for accurate screening and monitoring of mild cognitive impairment (MCI) and early dementia. · BeCare Link (Rumson, NJ): Gamified, mobile app for the remote, objective, and quantitative assessment of neurological function and decline using AI. · Deliberate AI (New York, NY): Multi-modal diagnostics platform and machine learning model for the analysis of behavioral and physiological biomarkers to detect symptoms and monitor patients with psychiatric and neurological conditions. · Head Diagnostics Ltd (Dublin, Ireland): A novel, hand-held medical device measuring ocular microtremor (OMT) enabling the rapid, non-invasive assessment of Parkinson’s disease. · HealthQb Technologies (Vancouver BC, Canada): A biopsychosocial behavior modification system for pain and chronic disease which objectively measures, prioritizes, and targets a patient’s personalized “hidden” psycho-social factors that contribute to their persistent illness. · Modus Health (Edmonds, WA): Wearable and validated digital endpoints for measuring real-world walking quantity, intensity, and duration, with demonstrated superior accuracy compared to other wearable mobility assessment tools. · Neuroventis (Brussels, Belgium): Neurological patient and HCP engagement platform offering services and programs to deliver optimal patient outcomes, improved medication adherence, and generation of real-world data. · Orbit Health (Munich, Germany): AI-enabled platform using commercially available smartwatches to offer objective, convenient, minute-by-minute information on motor symptoms and treatment response in Parkinson’s patients, in real-world settings. · REACT Neuro (Cambridge, MA): Self-administered, in home, virtual reality platform for quantitative, comprehensive, and objective neurocognitive assessments. · Vistim Labs Inc. (Salt Lake City, UT): Novel functional EEG-based, AI-enabled cognitive assessment collecting real-time stimulated brain activity to enable objective measurement of early, previously imperceivable changes in cognitive function. · WKD.SMRT (Cambridge, MA): Pre-configured, video-based and sensor-based, in-home platform that passively, ambiently, and continuously collects objective, high-quality, real-world data on motor and functional performance.
PharmStars is accepting applications until July 16 for its Fall 2022 cohort, themed “Innovations in Real-World Evidence.” For digital health startups interested in participating, information on dates, deadlines, and the application form is available on the PharmStars website.
PharmStars 2022 membership is now open to a limited number of additional pharma and biotech companies.
PharmStars is the member-based, pharma-focused accelerator for digital health startups. Through our extensive expertise across pharma, startups, digital health, and innovation, we understand the challenges that pharma and startups face when seeking to collaborate. Our PharmaU program supports digital health startups and our pharma members in “bridging the pharma-startup gap,” leading to greater success and faster adoption of “beyond the molecule” solutions for patients.
QUAI DAO Global DeFi Accelerator helps projects unlock their potential by providing a diverse spectrum of services by Utilizing its expert team and resources to provide projects a clear path for their go-to-market strategy while assuring investors that projects on boarded by QUAI are vetted and professionally developed.
QUAI is setting the standard for DeFi Accelerators and DeFi focused investment platforms, by on-boarding carefully selected projects that are innovative and have sustainable growth potential.
“Innovations in the DeFi industry should provide a frictionless experience for the user, as DeFi develops and continues to replace inefficient traditional financial markets. User experience, the ease of use is paramount to creating a successful DeFi protocol”, says Victor Yampolsky, co-founder of QUAI DAO.
QUAI DAO has already amassed a substantial pipeline of projects, each carefully selected project being a first mover in their relevant addressable market. Another highly anticipated announcement for new projects accelerated by QUAI is a new partnership for the creation of the first DeFi Experiences and Merchandising Platform for Soccer.
On May 30th, at 10:00 UTC, HotBit will be hosting an AMA with the QUAI DAO co-founder in the official HotBit Telegram group. The focus of the upcoming discussion is what QUAI DAO has accomplished and what awaits QUAI token holders on the near-term horizon for 2021, such projects as QUAI Invest/QUAI Interchange, MeDIA eYe NFT Ads Creator Portal, ASKOLEND on BSC, and other projects.
About QUAI DAO
QUAI DAO is a platform for investors and professionals focused on creating sustainable value by generating consistent capital yields while accelerating technologically innovative projects. QUAI DAO can support innovative DeFi projects in their development while providing investors the opportunity to receive consistent yields and maximize ROI on capital allocations.
HotBit is one of the largest cryptocurrency exchanges. Founded in 2018, HotBit has listed 547 trading pairs, as per CoinMarketCap on October 14th, 2019, and has accumulated over 1 million registered users from more than 170 countries. This exchange provides high liquidity and safety both for projects and traders.
NEC Corporation, a leader in IT and network technologies; NEC X, the innovation accelerator for NEC’s emerging technologies; and Alchemist Accelerator, a venture-backed initiative focused on accelerating the development of early-stage ventures, today announced a joint partnership between NEC X and Alchemist to provide technology startups with end-to-end support, including NEC R&D technologies and business launch coordination. NEC X provides its Corporate Accelerator Program (CAP) together with AlchemistX, Alchemist’s corporate innovation accelerator, to speed the development of early-stage startups.
“Our CAP has evolved by leveraging the Silicon Valley startup ecosystem,” said Shige Ihara, CEO of NEC X. “From its establishment in 2018 to the present, NEC X has gone from being a new startup itself, to seeding 23 potential new ventures. However, we wanted to enhance the support for startups to succeed through our technology incubation program. We chose to partner with Alchemist because it was a good fit for all parties.”
NEC X has access to Alchemist’s methodology and resources, as well as the Alchemist network of entrepreneurs, venture capitalists, corporations, and mentors. Additionally, NEC X CAP graduates have the option to join Alchemist for further growth and investment opportunity. Alchemist has access to NEC X’s early-stage startups using cutting-edge technologies from NEC R&D.
“We are excited to partner with NEC X–we think the synergies are strong. NEC is pushing the frontiers of technology, and Alchemist bolsters NEC X’s existing support with a structured path to market traction and fundraising as well as mentorship and community for founders,” said Ravi Belani, managing director and founder at Alchemist Accelerator. “Alchemist has built a strong track record of helping startups realize and expand their potential, including accelerating their growth through hands-on coaching and curated access to fundraising. We are excited to now support NEC X’s startups, in which much of the experience is personalized to the needs of each startup to help them build their company in the way that works for them.”
Additionally, NEC X and Alchemist are pleased to announce the graduation of new windowMetabob at the Alchemist 27th Demo Day today. Metabob, which helps Python coders save countless hours by quickly identifying bugs in their code, began in NEC X’s CAP, using technology developed from NEC R&D. After incubation and spin out through NEC X, Metabob joined Alchemist for final acceleration and launch.
The NEC X CAP process begins by introducing prequalified entrepreneurs-in-residence (EIRs), who have the right mix of business acumen and technology aptitude, to technologies from NEC R&D, and then the potential EIRs present and demonstrate business ideas. Those selected as EIRs then drive the CAP process, including customer discovery and customer validation, and go through development activities for incorporation. Since its establishment in 2018, NEC X has already spun out three startups through the CAP process.
Those interested in participating in the NEC X Corporate Accelerator Program as EIRs, partners or investors can visit https://nec-x.com or email [email protected] to request a meeting.
For more information about Alchemist, please visit: https://www.alchemistaccelerator.com/.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.
About NEC X
NEC X, Inc. accelerates the development of innovative products and services through the strengths of NEC Laboratories’ technologies. The organization was launched by NEC Corp. in 2018 to fast-track technologies and business ideas selected from inside and outside NEC. For companies launched by its Corporate Accelerator Program, NEC X supports business development activities to help achieve revenue growth. NEC X also provides options for entrepreneurs, startups and existing companies in the Americas to use NEC’s emerging technologies. The company is centrally located in Silicon Valley for access to its entrepreneurial ecosystem and strong high technology market. Learn more at https://nec-x.com or by emailing [email protected].
Alchemist is a venture-backed accelerator focused on the development of seed-stage ventures that monetize from enterprises (not consumers). CB Insights rated Alchemist the top accelerator based on median funding rates of its grads (YC was #2). Alchemist backers include many of the top corporate and VC funds–including Khosla Ventures, DFJ, Cisco, Siemens, GE, and Salesforce, among others. Notable alums include LaunchDarkly, Rigetti Quantum Computing, Privacera, mPharma, Matternet, and Mightyhive. Learn more at https://www.alchemistaccelerator.com or by emailing [email protected].
Metabob is an AI code review tool helping developers save countless hours on their debugging time by identifying critical bugs other tools in the market tend to miss. For more information, please visit: new windowhttps://metabob.com/.